在癌症免疫中,与天生的T细胞和microRNAs之间的相互作用
Mohammad Javad Yousefi1,2, Yashmin Afshar3, Amirmohammad Amoozadehsamakoosh2,3,4
1Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
Discover oncology
|July 28, 2025
概括
天生的类似T细胞 (ILTCs) 由于其独特的抗瘤活动,在癌症免疫治疗中表现有前途. 微RNAs (miRNAs) 显著影响ILTC功能,为癌症治疗提供了新的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 天生的类似T细胞 (ILTCs) 是癌症免疫治疗中的新兴目标.
- ILTCs具有独特的抗原识别和抗瘤特性,但也表现出双重的亲和抗瘤作用.
- 微RNAs (miRNAs) 是基因表达的关键调节者,影响癌症中的ILTC功能.
研究的目的:
- 审查ILTCs和miRNAs在癌症中的复杂相互作用.
- 探索miRNAs如何调节ILTC活动和癌症进展.
- 突出针对miRNA-ILTC相互作用的新型治疗策略.
主要方法:
- 对ILTCs,miRNAs和癌症研究的文献综述.
- 在瘤细胞,ILTC和外体细胞中分析miRNA角色 (例如miR-155,let-7,miR-181a).
- 检查治疗方法,包括miRNA修饰和CAR-T细胞策略.
主要成果:
- 瘤和免疫细胞中的miRNA表达协同影响ILTC功能和癌症进展.
- 具体的miRNAs可以根据上下文作为瘤促进剂或抑制剂.
- miRNA失调影响ILTC活动,影响瘤微环境.
结论:
- 针对miRNA-ILTC相互作用为癌症免疫治疗提供了一个有希望的途径.
- 调节miRNA表达可以增强ILTC抗瘤功能.
- 创新的治疗策略,包括CAR-T细胞,通过通过miRNAs调节ILTCs来改善癌症治疗的潜力.
相关概念视频
MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Cytotoxic T Cells-mediated Immune Response
2.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.1K
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Tumor Immunotherapy
662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662
lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K


